Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
OSAKA, Japan -- Takeda ( TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Read More
Recent Posts
Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
UK Boosts Support For Offshore Wind in Bumper Auction
Ireland Is Trying to Get Back on the Data Center Bandwagon
Notice Concerning Change of Representative Executive Officer
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
